60 Degrees Pharmaceuticals, Inc. (SXTP) Earnings History
Annual and quarterly earnings data from 2020 to 2024
Loading earnings history...
SXTP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SXTP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 36.7% | -1599.0% | -1308.0% |
| 2023 | -87.1% | -2032.8% | -1485.1% |
| 2022 | -93.7% | -784.2% | -2769.5% |
| 2021 | 26.7% | -96.9% | -366.4% |
| 2020 | 67.8% | -19.2% | -139.1% |
Download Data
Export SXTP earnings history in CSV or JSON format
Free sign-in required to download data
60 Degrees Pharmaceuticals, Inc. (SXTP) Earnings Overview
As of May 8, 2026, 60 Degrees Pharmaceuticals, Inc. (SXTP) reported trailing twelve-month net income of -$8M, reflecting -1852.6% year-over-year growth. The company earned $-2.17 per diluted share over the past four quarters, with a net profit margin of -1308.0%.
Looking at the long-term picture, SXTP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2020.
60 Degrees Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AEYE (-$3M net income, -7.6% margin), MTNB (-$17M net income), GERN (-$70M net income, -46.7% margin), SXTP has room to improve margins relative to the peer group. Compare SXTP vs AEYE →
SXTP Earnings vs Peers
Earnings metrics vs comparable public companies
SXTP Historical Earnings Data (2020–2024)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$8M | -111.0% | -$10M | $-18.55 | -1308.0% | -1599.0% |
| 2023 | -$4M | +39.1% | -$5M | $-0.95 | -1485.1% | -2032.8% |
| 2022 | -$6M | -45.4% | -$2M | $-1.07 | -2769.5% | -784.2% |
| 2021 | -$4M | -40.1% | -$1M | $-0.74 | -366.4% | -96.9% |
| 2020 | -$3M | - | $-418,130 | $-0.52 | -139.1% | -19.2% |
See SXTP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SXTP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SXTP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSXTP — Frequently Asked Questions
Quick answers to the most common questions about buying SXTP stock.
Is SXTP growing earnings?
SXTP EPS fell to $-2.17, with earnings declining -1852.6%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-8M.
What are SXTP's profit margins?
60 Degrees Pharmaceuticals, Inc. net margin is -1308.0%, with operating margin at -1599.0%. Below-average margins reflect competitive or cost pressures.
How consistent are SXTP's earnings?
SXTP earnings data spans 2020-2024. The declining earnings trend is -1852.6% YoY. Historical data enables comparison across business cycles.